Can Red Light Therapy Improve Eyesight & Is It Safe for the Eyes? - Red Light Hero

Can Red Light Therapy Improve Eyesight & Is It Safe for the Eyes?

First published
Last reviewed
Reading time
5 min read

In short

Red and near-infrared light has been trialled in specific eye conditions, mostly dry macular degeneration, with clinic devices that aim set doses into the eye - and some of those trials are encouraging, while the reviews say more and larger ones are needed. The myopia work in children uses a laser, which is a different device with a published case of retinal damage.

Nobody has studied years of panel use on eyes, so our panels ship with goggles and the choice stays with you and your eye specialist.

Key takeaways

  1. The strongest human evidence is in dry age-related macular degeneration: a 100-person sham-controlled trial of 590, 660 and 850nm light gained 2.4 letters over sham at 13 months.Read this section: What has actually been studied
  2. The myopia studies in children use a 650nm laser looked at directly for minutes a day - a different device from a panel, and one with a published case of retinal damage.Read this section: The myopia work is a different device
  3. Cell and animal studies show red and near-infrared light protecting retinal cells, which explains the interest but is not evidence of benefit in people.Read this section: What the lab studies add
  4. No study has followed panel users' eyes over years. The eye trials report good tolerability at set doses aimed into the eye; a panel is far brighter to look at, so we ship goggles and leave the decision with you and your eye specialist.Read this section: Is it safe for the eyes?

Two questions come up together: can red light do anything for eyesight, and is it safe to use a panel with your eyes open? The honest answer to the first is "it has been studied in specific eye conditions, with specific devices, and some of those trials are encouraging". The honest answer to the second is longer, so it gets its own section.

What has actually been studied

The strongest human evidence is in dry age-related macular degeneration. LIGHTSITE III, a randomised sham-controlled trial of 100 people, delivered 590, 660 and 850nm light in nine-session courses every four months and found a 5.4-letter gain in visual acuity at 13 months against 3.0 letters for sham, with fewer treated eyes developing new geographic atrophy and a favourable safety profile. The gap of 2.4 letters is real but modest, and five of the authors work for the device company. A second device, using 630nm red with 590nm yellow, was tested in 76 patients: two sessions a week for four weeks, with a significant change in best-corrected acuity at four months and only mild ocular adverse events in a fifth of the treated group. Earlier and smaller: 670nm LED light reduced drusen volume and improved acuity and contrast sensitivity in 42 eyes, and nine 670nm sessions improved acuity and visual field in a short-term study.

A 2023 narrative review of all of this is worth reading for its caution: early results for acuity and contrast sensitivity are encouraging, but with only three randomised trials, varied protocols and small samples, whether the treatment slows progression to advanced AMD is still uncertain. Beyond AMD, twelve people with retinitis pigmentosa had nine sessions of the same three wavelengths: acuity improved from 0.62 to 0.53 logMAR four weeks later, visual field measures were numerically but not significantly better, and there were no adverse effects on OCT or ERG. An open study, so no sham arm. Our eyesight research page lists all of these by wavelength.

The myopia work is a different device

You may have seen headlines about red light slowing short-sightedness in children. That work, mostly from China, uses a different thing: a 2022 review describes a 650nm low-level laser at about 2 mW that the child looks into for a few minutes a day, and concludes it may be a useful tool while calling for more studies. It is a laser aimed into the eye, not a panel across a room, and it has a published cautionary case: retinal damage in a 12-year-old after repeated low-level red-light laser exposure. We mention it because the two get mixed up, and because it is the clearest reason not to point any laser at your eyes without an ophthalmologist involved.

What the lab studies add

Cell and animal work explains why researchers went looking. 670nm light increased the ability of human retinal pigment cells to clear debris; ten minutes of 810nm or 670nm light protected mouse retinal tissue after six hours of damaging blue light, boosting mitochondrial energy metabolism and cutting cell death; and daily 830nm LED sessions preserved photoreceptors in a rat model of retinitis pigmentosa, with the benefit fading once treatment stopped. These are mechanism, not benefit in people. They are also the reason the eye trials chose the wavelengths they did.

A curious one: light on the back

In 2025 a group of vision researchers put 25 adults under an 850nm LED panel for 15 minutes with the light on the bare back, and measured colour vision a day later: blue-yellow colour-contrast thresholds improved by 16%, and still by 7% in a group whose heads were wrapped in foil so no light reached the eyes. Sham exposure did nothing. The authors read it as a body-wide mitochondrial effect; it is one study of 25 people and needs repeating, but it is the first hint that a panel session might reach the eyes without the eyes being in the light at all.

Is it safe for the eyes?

What we can say with sources: the eye trials above aimed light into the eye at set doses and reported good tolerability, from a favourable safety profile over 13 months to no adverse effects on OCT or ERG. Red and near-infrared also sit at the bottom of the retinal hazard scale that lighting standards use - the one that puts blue near the top - which we explained in the blue light post.

What we cannot say: nobody has followed panel users' eyes over years, because nobody has done that study. A panel is far brighter to look at than a clinic device, and the natural reaction is to close your eyes. So every panel ships with goggles, spare eye protection is on the site, and the decision belongs with you and your eye specialist - particularly if you have an eye condition, take medication that increases light sensitivity, or are using a laser device of any kind. An earlier version of this post cited a review of light therapy for mood disorders as evidence of eye safety; it was about bright white light boxes, not red panels, so it is gone.

What we suggest

Wear the goggles or close your eyes in front of a panel, keep lasers away from your eyes unless an ophthalmologist is involved, and if you have an eye condition, ask your specialist before you start. If you want the studies, the eyesight research page has them; if you want to ask, contact us.

References

Our sources for this article along with direct links and the reason we chose to cite it.

  1. Boyer et al. (2024). LIGHTSITE III: 13-month efficacy and safety evaluation of multiwavelength photobiomodulation in nonexudative (dry) age-related macular degeneration using the LumiThera Valeda light delivery system. RetinaWhy we cite it: The randomised sham-controlled trial of 100 people behind the 2.4-letter figure; five authors are employees or contractors of the device company.
  2. Borrelli et al. (2024). Safety, tolerability, and short-term efficacy of low-level light therapy for dry age-related macular degeneration. Ophthalmology and TherapyWhy we cite it: The 76-patient EYE-LIGHT trial (590 and 630nm, two sessions a week for four weeks); a preliminary analysis at four months.
  3. Fantaguzzi et al. (2023). Shedding light on photobiomodulation therapy for age-related macular degeneration: a narrative review. Ophthalmology and TherapyWhy we cite it: The review that calls the results encouraging and the evidence thin - three randomised trials, varied protocols, small samples.
  4. Siqueira, Pinho and Brandão (2024). Short-term results of multiwavelength photobiomodulation in retinitis pigmentosa. Clinical OphthalmologyWhy we cite it: The twelve-person open study in retinitis pigmentosa; no sham arm, four-week follow-up.
  5. Merry et al. (2017). Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta OphthalmologicaWhy we cite it: The 42-eye study of multi-wavelength LED light including 670nm; an early, uncontrolled result.
  6. Siqueira et al. (2021). Short-term results of photobiomodulation using light-emitting diode light of 670 nm in eyes with age-related macular degeneration. Photobiomodulation, Photomedicine and Laser SurgeryWhy we cite it: The nine-session 670nm study; short-term and small.
  7. Huang et al. (2022). Red light irradiation as an intervention for myopia. Indian Journal of OphthalmologyWhy we cite it: The review of the Chinese myopia work; it is where the 650nm, 2 mW laser description comes from.
  8. Liu et al. (2023). Retinal damage after repeated low-level red-light laser exposure. JAMA OphthalmologyWhy we cite it: The case report of retinal damage in a 12-year-old using a low-level red-light laser for myopia; the reason the laser work is kept separate from panels.
  9. Fuma et al. (2015). Photobiomodulation with 670 nm light increased phagocytosis in human retinal pigment epithelial cells. Molecular VisionWhy we cite it: A cell study: mechanism, not benefit in people.
  10. Heinig et al. (2020). Photobiomodulation mediates neuroprotection against blue light induced retinal photoreceptor degeneration. International Journal of Molecular SciencesWhy we cite it: The mouse retinal tissue study of 810 and 670nm light after blue-light damage; animal tissue, not people.
  11. Gopalakrishnan et al. (2020). Photobiomodulation preserves mitochondrial redox state and is retinoprotective in a rodent model of retinitis pigmentosa. Scientific ReportsWhy we cite it: The rat study of daily 830nm LED sessions; the benefit faded when treatment stopped.
  12. Jeffery et al. (2025). Longer wavelengths in sunlight pass through the human body and have a systemic impact which improves vision. Scientific ReportsWhy we cite it: The 25-person study of 850nm light on the back improving colour vision a day later, even with the eyes shielded; one study, needs repeating.

About the author

Helmut Uhlmann

Helmut Uhlmann

Founder, Red Light Hero

Helmut Uhlmann founded Red Light Hero and writes this blog. He delves deep into the research and is passionate about helping people get the most out of red light therapy.

Our story

Speak to us

Questions about this article, or about which device fits what you want to do? Email us or leave a comment. Advice is complimentary and there is no obligation to buy anything.

Disclaimer

Red Light Hero devices use clinical-grade LEDs but are not included in the ARTG and are not intended to treat or prevent disease. The research discussed here is about the wavelengths and technologies we use, not about our products. This article is educational information only, not medical advice - check with your healthcare professional before use, particularly if you are pregnant, take medication that increases light sensitivity, or have a condition affecting your eyes or skin.

Leave a comment

Please note, comments need to be approved before they are published.

Back to blog